Autism Spectrum Disorder (ASD) is characterized by cognitive deficits. The most typical features are impairments of communication, social skills and repetitive behaviors. New research into postmortem has shown neuroinflammation is more commonplace in ASD patients.
For more than a decade, I have been integrating medical cannabis into the treatment of special-needs children in my holistic
The endocannabinoid system (ECS) has recently shown to affect social behaviors associated with ASD. The ECS is a ‘neuromodulatory’ system. It regulates emotional responses, behavioral reactions and how they relate to context, and social interaction. The ECS has also been shown to play a role in specific conditions that are often similar with ASD. These include seizures, anxiety, intellectual disabilities, and sleep pattern disturbances.
Only a few novel studies have explored the relationship between the ECS and ASD. Many of these studies have been pre-clinical in nature, meaning they were pharmacological modifications in animal models. They look at ASD-like behaviors in animal models to assess the viability of moving forward to clinical tests. Given the promising results from pre-clinical studies, clinical trials are now ongoing.
Giving oxytocin to patients with ASD alleviates key symptoms. Cognitive function improves in processing social information, recognizing others’ emotions, understanding social interactions, increasing eye contact, and reducing repetitive patterns. There is a general effect of cannabinoids on subsets of neuroendocrine cells, including neurons that secrete oxytocin and vasopressin.
cannabisMD gathers a range of scientific data to best inform our readers on conventional and alternative therapies to conditions like ASD. We explore not only medical cannabis or CBD as a treatment, but explore the viability of other new trends and traditional therapies. ASD remains largely untreated. cannabisMD explores solutions with a critical eye so that you can address your health concerns from an educated position.